- Просто удивительная копия.
- Szöllősi János - Google Scholar
- HUA2 - Módszer prosztatatúltengés és prosztatarák kezelésére - Google Patents
- Ilona Pálné Kovács - Google Scholar
- Prostate cancer prognosis uk
- Prostatitis és anabolikus szteroidok
The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Genes Chromosomes Cancer ; — Current state of ERG as biomarker in prostatic adenocarcinoma.
Curr Cancer Drug Targets ; — The molecular taxonomy of primary prostate cancer. Cell ; — The mutational landscape of prostate cancer.
Eur Urol. Nat Genet. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Neoplasia ; 14— Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer. Eur J Cancer ; — Integrative clinical genomics of advanced prostate cancer.
Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. The mutational landscape of lethal castration-resistant prostate cancer.
Nature ; — Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med.
Increased survival with enzalutamide in prostate cancer after chemotherapy. Abiraterone in metastatic prostate cancer without previous chemotherapy.
HU0000261A2 - Módszer prosztatatúltengés és prosztatarák kezelésére - Google Patents
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer PREVAIL : results from a randomised, phase 3 trial.
- A prosztatitis és a kezelés diagramja
- Must understand and voluntarily sign a written informed consent prior to any study-related procedures being performed.
- Gyulladás csökkentése a szervezetben
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Genetic alterations in the PI3K pathway in prostate cancer.
Anticancer Res. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer ; — Combination AZD with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models.
Mol Cancer Ther. Abi alone in patients with metastatic castration-resistant prostate cancer mCRPC after volume prostata 40 cc chemotherapy A. J Clin Oncol.
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Clin Cancer Res. Spatial genomic heterogeneity within localized, multifocal prostate cancer. The importance of DNA methylation in prostate cancer development.
J Steroid Biochem Mol Biol.